Almirall obtains approval from EC for atopic dermatitis therapy
EBGLYSS is intended for patients aged 12 years and above who are candidates for systemic therapy. The company plans to begin selling the product in Germany initially and
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted in favour of Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma (idecabtagene vicleucel) for treating triple-class exposed relapsed or refractory multiple myeloma.